Cargando…

Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents

We established the following two variants of the MOLM-13 human acute myeloid leukemia (AML) cell line: (i) MOLM-13/DAC cells are resistant to 5-aza-2′-deoxycytidine (DAC), and (ii) MOLM-13/AZA are resistant to 5-azacytidine (AZA). Both cell variants were obtained through a six-month selection/adapta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janotka, Ľuboš, Messingerová, Lucia, Šimoničová, Kristína, Kavcová, Helena, Elefantová, Katarína, Sulová, Zdena, Breier, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923013/ https://www.ncbi.nlm.nih.gov/pubmed/33669837 http://dx.doi.org/10.3390/ijms22042076

Ejemplares similares

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol
por: Šimoničová, Kristína, et al.
Publicado: (2023)

Detection of the Mitochondrial Membrane Potential by the Cationic Dye JC-1 in L1210 Cells with Massive Overexpression of the Plasma Membrane ABCB1 Drug Transporter
por: Elefantova, Katarina, et al.
Publicado: (2018)

Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5
por: Hur, Eun-Hye, et al.
Publicado: (2016)

Detection of Glycomic Alterations Induced by Overexpression of P-Glycoprotein on the Surfaces of L1210 Cells Using Sialic Acid Binding Lectins
por: Bubencíkova, Tatiana, et al.
Publicado: (2012)

Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway
por: Kocibalova, Zuzana, et al.
Publicado: (2021)

Development of Resistance to Endoplasmic Reticulum Stress-Inducing Agents in Mouse Leukemic L1210 Cells
por: Cagala, Martin, et al.
Publicado: (2020)

Screening of Phenanthroquinolizidine Alkaloid Derivatives for Inducing Cell Death of L1210 Leukemia Cells with Negative and Positive P-glycoprotein Expression
por: Kubíčková, Jana, et al.
Publicado: (2019)

The Roles of microRNAs in Cancer Multidrug Resistance
por: Pavlíková, Lucia, et al.
Publicado: (2022)

Cell Death Effects Induced by Sulforaphane and Allyl Isothiocyanate on P-Glycoprotein Positive and Negative Variants in L1210 Cells
por: Kontar, Szilvia, et al.
Publicado: (2020)

Betulinic Acid–Doxorubicin-Drug Combination Induced Apoptotic Death via ROS Stimulation in a Relapsed AML MOLM-13 Cell Model
por: Vu, Milan, et al.
Publicado: (2021)

Potentiation of Anticancer Drugs: Effects of Pentoxifylline on Neoplastic Cells
por: Barancik, Miroslav, et al.
Publicado: (2011)

Interplay between P-Glycoprotein Expression and Resistance to Endoplasmic Reticulum Stressors
por: Hano, Milan, et al.
Publicado: (2018)

L1210 Cells Overexpressing ABCB1 Drug Transporters Are Resistant to Inhibitors of the N- and O-glycosylation of Proteins
por: Pavlikova, Lucia, et al.
Publicado: (2017)

Overexpression of GRP78/BiP in P-Glycoprotein-Positive L1210 Cells is Responsible for Altered Response of Cells to Tunicamycin as a Stressor of the Endoplasmic Reticulum
por: Šereš, Mário, et al.
Publicado: (2020)

Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR Leukemia Cells
por: Kyca, Tomáš, et al.
Publicado: (2021)

Highly stereocontrolled total synthesis of racemic codonopsinol B through isoxazolidine-4,5-diol vinylation
por: Ďurina, Lukáš, et al.
Publicado: (2021)

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13
por: Prajapati, Subhash C, et al.
Publicado: (2022)

Effects of Sulforaphane-Induced Cell Death upon Repeated Passage of Either P-Glycoprotein-Negative or P-Glycoprotein-Positive L1210 Cell Variants
por: Bertova, Anna, et al.
Publicado: (2022)

Triorganotin Derivatives Induce Cell Death Effects on L1210 Leukemia Cells at Submicromolar Concentrations Independently of P-glycoprotein Expression
por: Bohacova, Viera, et al.
Publicado: (2018)

Tunicamycin Depresses P-Glycoprotein Glycosylation Without an Effect on Its Membrane Localization and Drug Efflux Activity in L1210 Cells
por: Šereš, Mário, et al.
Publicado: (2011)

Doxorubicin selectively induces apoptosis through the inhibition of a novel isoform of Bcl-2 in acute myeloid leukaemia MOLM-13 cells with reduced Beclin 1 expression
por: Vu, Milan, et al.
Publicado: (2020)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
por: Fooks, Katie, et al.
Publicado: (2022)

Lack of cross‐resistance to FF‐10501, an inhibitor of inosine‐5′‐monophosphate dehydrogenase, in azacitidine‐resistant cell lines selected from SKM‐1 and MOLM‐13 leukemia cell lines
por: Murase, Motohiko, et al.
Publicado: (2016)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
por: Srivastava, Pragya, et al.
Publicado: (2016)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein
por: Halasova, E, et al.
Publicado: (2010)

Effect of Different Fat and Moringa oleifera Leaf Meal (MOLM) Inclusion Levels on Proximate Composition, Fatty Acid Profile, and Lipid Oxidation of Chicken Droëwors
por: Tembela, Nelisiwe, et al.
Publicado: (2022)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
por: Kordella, Chryssoula, et al.
Publicado: (2021)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Expression of anti-apoptotic protein survivin and tumor suppressor p53 protein in patients with pulmonary carcinoma
por: Halasová, E, et al.
Publicado: (2009)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents
por: Malkaram, Sridhar A, et al.
Publicado: (2022)

The use of hypomethylating agents in hematologic malignancies: treatment preferences and results
por: Serin, Istemi, et al.
Publicado: (2021)

PB1846: MANAGEMENT OF PATIENTS TREATED WITH VENETOCLAX WITH HYPOMETHYLATING AGENTS: LONG-TERM INCIDENCE OF CYTOPENIAS AND INFECTIONS
por: Guardia-Torrelles, Ares, et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4gej5a8vd1iculjjppl35ali6u